zinpentraxin alfa

Zinpentraxin alfa (PRM-151) is a recombinant form of human pentraxin-2 (rhPTX-2), a naturally occurring circulating plasma protein synthesized in the liver. Developed by Roche (following the acquisition of Promedior), it was primarily investigated for the treatment of idiopathic pulmonary fibrosis (IPF). The drug's mechanism involves the modulation of monocyte-derived cells, specifically macrophages and fibrocytes, which are key drivers of the fibrotic process. By mimicking endogenous pentraxin-2, the drug acts to inhibit and potentially reverse fibrosis by regulating the innate immune response to tissue injury. Despite showing promise in Phase II trials, the pivotal Phase III STARSCAPE trial was terminated early in November 2022 after a prespecified futility analysis concluded that the drug was unlikely to demonstrate a clinical benefit over placebo in slowing the decline of forced vital capacity (FVC).

Brand names

PRM-151PRM151PRM 151

Other names

recombinant human pentraxin-2rhPTX-2rhPTX2rhPTX 2recombinant human Serum Amyloid P